Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tresiba insulin degludec: Clinical trial start

Novo Nordisk disclosed in its 1Q13 earnings that it plans to start "within a year" the FDA-requested CV outcomes trial of Tresiba insulin degludec and Ryzodeg insulin

Read the full 272 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE